← Back

ENDRA Life Sciences Inc

6.31+1.6%1Y · USD

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology, which uses a pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves for high-contrast imaging. Its intended applications include non-alcoholic fatty liver disease, tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. Incorporated in 2007, the company is based in Ann Arbor, Michigan.

Price · split & dividend adjusted
News & notes moving NDRA
NDRA▼

Halper Sadeh LLC Investigates BOLD and NDRA Mergers for Shareholder Fairness

Halper Sadeh LLC, an investor rights law firm, is investigating Boundless Bio and ENDRA Life Sciences over their proposed mergers, citing concerns that shareholders may not be receiving fair deals. The firm says insiders could obtain substantial financial benefits not available to ordinary shareholders, and the transactions may contain terms that limit superior competing offers. Boundless Bio shareholders are expected to own approximately 3.7% of the combined company after its merger with Serapha Bio, while ENDRA shareholders would hold about 3% following its merger with Noble Africa. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders, and encourages them to contact the firm at no cost to discuss their rights.
BOLD ▼NDRA ▼
BOLD · Regulation · Negative Investigation into merger fairness may lead to increased scrutiny or deal changes, harming shareholders.
NDRA · Regulation · Negative Investigation into merger fairness may lead to increased scrutiny or deal changes, harming shareholders.
Read original ↗
GlobeNewswire·95dRead more →
NDRA

ASP Isotopes announces proposed merger of Noble Africa with ENDRA Life Sciences and $50 million private placement

ASP Isotopes announced that its wholly-owned subsidiary Noble Africa will merge with a subsidiary of ENDRA Life Sciences, with Noble Africa surviving and applying to list on Nasdaq under the ticker NOBA. The combined company will serve as a helium platform for Renergen’s Virginia Gas Project. A concurrent private placement is expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes as lead investor and roughly $30 million from other investors. Upon closing, ASP Isotopes is expected to own approximately 89% of the combined company, pre-closing ENDRA stockholders about 3%, and private placement investors other than ASPI about 7%. The transaction has been approved by both companies’ boards and is expected to close in the third or fourth quarter of 2026, subject to regulatory and stockholder approvals.
ASPI ▲NDRA
ASPI · Capital · Positive ASP Isotopes leads $50M private placement and will own 89% of merged helium platform, providing capital and strategic control.
Noble Africa LLC · Capital · Positive Noble Africa will survive the merger and list on Nasdaq as NOBA, gaining access to public markets and $50M in funding.
Renergen Limited · Demand · Positive The merged company will serve as a helium platform for Renergen's Virginia Gas Project, securing a dedicated offtake and funding channel.
NDRA · Capital · Neutral ENDRA Life Sciences subsidiary is being merged into Noble Africa; pre-closing ENDRA stockholders will own only ~3% of the combined entity.
Read original ↗
GlobeNewswire·102dRead more →
© 2026 MarketDXAsset